The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome.

<h4>Objective</h4>The role of the hydroxycarboxylic acid receptor 2 (HCA2) in the retinal damage induced by diabetes has never been explored. In this context, the present study highlights an upregulation of retinal HCA2 receptors in diabetic C57BL6J mice. Moreover, we illustrate that HCA...

Full description

Bibliographic Details
Main Authors: Maria Consiglia Trotta, Rosa Maisto, Francesca Guida, Serena Boccella, Livio Luongo, Cornel Balta, Giovanbattista D'Amico, Hildegard Herman, Anca Hermenean, Claudio Bucolo, Michele D'Amico
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0211005
id doaj-39f08790eb6242bc97619700802604e9
record_format Article
spelling doaj-39f08790eb6242bc97619700802604e92021-03-04T10:37:22ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01141e021100510.1371/journal.pone.0211005The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome.Maria Consiglia TrottaRosa MaistoFrancesca GuidaSerena BoccellaLivio LuongoCornel BaltaGiovanbattista D'AmicoHildegard HermanAnca HermeneanClaudio BucoloMichele D'Amico<h4>Objective</h4>The role of the hydroxycarboxylic acid receptor 2 (HCA2) in the retinal damage induced by diabetes has never been explored. In this context, the present study highlights an upregulation of retinal HCA2 receptors in diabetic C57BL6J mice. Moreover, we illustrate that HCA2 receptors exert an anti-inflammatory effect on the retinal damage induced by diabetes when activated by the endogenous ligand β-hydroxybutyrate.<h4>Methodology</h4>Seven-to-10-week-old C57BL6J mice were rendered diabetic by a single intraperitoneal injection of streptozotocin (75 mg/kg of body weight) and monitored intermittently over a 10-week period extending from the initial diabetes assessment. Mice with a fasting blood glucose level higher than 250 mg/dl for 2 consecutive weeks after streptozotocin injection were treated twice a week with intraperitoneal injections of 25-50-100 mg/kg β-hydroxybutyrate.<h4>Results</h4>Interestingly, while the retinal endoplasmic reticulum stress markers (pPERK, pIRE1, ATF-6α) were elevated in diabetic C57BL6J mice, their levels were significantly reduced by the systemic intraperitoneal treatment with 50 mg/kg and 100 mg/kg β-hydroxybutyrate. These mice also exhibited high NLRP3 inflammasome activity and proinflammatory cytokine levels. In fact, the elevated levels of retinal NLRP3 inflammasome activation markers (NLRP3, ASC, caspase-1) and of the relative proinflammatory cytokines (IL-1β, IL-18) were significantly reduced by 50 mg/kg and 100 mg/kg β-hydroxybutyrate treatment. These doses also reduced the high apoptotic cell number exhibited by the diabetic mice in the retinal outer nuclear layer (ONL) and increased the ONL low connexin 43 expression, leading to an improvement in retinal permeability and homeostasis.<h4>Conclusions</h4>These data suggest that the systemic treatment of diabetic C57BL6J mice with BHB activates retinal HCA2 and inhibits local damage.https://doi.org/10.1371/journal.pone.0211005
collection DOAJ
language English
format Article
sources DOAJ
author Maria Consiglia Trotta
Rosa Maisto
Francesca Guida
Serena Boccella
Livio Luongo
Cornel Balta
Giovanbattista D'Amico
Hildegard Herman
Anca Hermenean
Claudio Bucolo
Michele D'Amico
spellingShingle Maria Consiglia Trotta
Rosa Maisto
Francesca Guida
Serena Boccella
Livio Luongo
Cornel Balta
Giovanbattista D'Amico
Hildegard Herman
Anca Hermenean
Claudio Bucolo
Michele D'Amico
The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome.
PLoS ONE
author_facet Maria Consiglia Trotta
Rosa Maisto
Francesca Guida
Serena Boccella
Livio Luongo
Cornel Balta
Giovanbattista D'Amico
Hildegard Herman
Anca Hermenean
Claudio Bucolo
Michele D'Amico
author_sort Maria Consiglia Trotta
title The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome.
title_short The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome.
title_full The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome.
title_fullStr The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome.
title_full_unstemmed The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome.
title_sort activation of retinal hca2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the nlrp3 inflammasome.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2019-01-01
description <h4>Objective</h4>The role of the hydroxycarboxylic acid receptor 2 (HCA2) in the retinal damage induced by diabetes has never been explored. In this context, the present study highlights an upregulation of retinal HCA2 receptors in diabetic C57BL6J mice. Moreover, we illustrate that HCA2 receptors exert an anti-inflammatory effect on the retinal damage induced by diabetes when activated by the endogenous ligand β-hydroxybutyrate.<h4>Methodology</h4>Seven-to-10-week-old C57BL6J mice were rendered diabetic by a single intraperitoneal injection of streptozotocin (75 mg/kg of body weight) and monitored intermittently over a 10-week period extending from the initial diabetes assessment. Mice with a fasting blood glucose level higher than 250 mg/dl for 2 consecutive weeks after streptozotocin injection were treated twice a week with intraperitoneal injections of 25-50-100 mg/kg β-hydroxybutyrate.<h4>Results</h4>Interestingly, while the retinal endoplasmic reticulum stress markers (pPERK, pIRE1, ATF-6α) were elevated in diabetic C57BL6J mice, their levels were significantly reduced by the systemic intraperitoneal treatment with 50 mg/kg and 100 mg/kg β-hydroxybutyrate. These mice also exhibited high NLRP3 inflammasome activity and proinflammatory cytokine levels. In fact, the elevated levels of retinal NLRP3 inflammasome activation markers (NLRP3, ASC, caspase-1) and of the relative proinflammatory cytokines (IL-1β, IL-18) were significantly reduced by 50 mg/kg and 100 mg/kg β-hydroxybutyrate treatment. These doses also reduced the high apoptotic cell number exhibited by the diabetic mice in the retinal outer nuclear layer (ONL) and increased the ONL low connexin 43 expression, leading to an improvement in retinal permeability and homeostasis.<h4>Conclusions</h4>These data suggest that the systemic treatment of diabetic C57BL6J mice with BHB activates retinal HCA2 and inhibits local damage.
url https://doi.org/10.1371/journal.pone.0211005
work_keys_str_mv AT mariaconsigliatrotta theactivationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome
AT rosamaisto theactivationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome
AT francescaguida theactivationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome
AT serenaboccella theactivationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome
AT livioluongo theactivationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome
AT cornelbalta theactivationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome
AT giovanbattistadamico theactivationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome
AT hildegardherman theactivationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome
AT ancahermenean theactivationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome
AT claudiobucolo theactivationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome
AT micheledamico theactivationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome
AT mariaconsigliatrotta activationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome
AT rosamaisto activationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome
AT francescaguida activationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome
AT serenaboccella activationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome
AT livioluongo activationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome
AT cornelbalta activationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome
AT giovanbattistadamico activationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome
AT hildegardherman activationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome
AT ancahermenean activationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome
AT claudiobucolo activationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome
AT micheledamico activationofretinalhca2receptorsbysystemicbetahydroxybutyrateinhibitsdiabeticretinaldamagethroughreductionofendoplasmicreticulumstressandthenlrp3inflammasome
_version_ 1714805211469447168